Gilead Sciences Inc.'s push to diversify away from HIV and into cardiovascular disease kicked into high gear with the proposed $1.4 billion acquisition of CV Therapeutics Inc. and positive data from a Phase III trial of Gilead's own resistant hypertension drug, darusentan.